CF Smackdown
  • Home
  • UPDATES
  • Grants
  • Research
  • Heroes
  • What is CF? Who we are Contact us
CF Smackdown
  • Home/
  • UPDATES/
  • Grants/
  • Research/
  • Heroes/
  • About/
    • What is CF?
    • Who we are
    • Contact us
Not-So-Invincible.jpg
CF Smackdown

End Cystic Fibrosis This Decade

UPDATES

Updates on CF Smackdown research, fundraising, and other practical efforts to help end cystic fibrosis this decade

CF Smackdown
  • Home/
  • UPDATES/
  • Grants/
  • Research/
  • Heroes/
  • About/
    • What is CF?
    • Who we are
    • Contact us
November 24, 2013

Estimated Prevalence of IVS8-5T in the U.S. Population

November 24, 2013/ Stephen Culp

Below is a back-of-the-napkin estimate of the prevalence of the 5T variant, and associated TG-repeat sequences, in the U.S. population. Please feel free to send us comments or corrections, as we want you to have as accurate a chart as possible. Click to enlarge.

November 24, 2013/ Stephen Culp/ Comment

Stephen Culp

  • The Smackdown Becomes a CFF ...
  • Announcing CF Smackdown grants
  • Home/
  • UPDATES/
  • Grants/
  • Research/
  • Heroes/
  • About/
    • What is CF?
    • Who we are
    • Contact us

CF Smackdown

The CF Smackdown's mission is to help end cystic fibrosis this decade.  We support and offer small seed grants to support CF research, writing, frank discussion, outreach, innovation, and families affected by cystic fibrosis. 


Categories

UPDATES
Kalydeco/Ivacaftor Need Not Be A $300,000 Orphan Drug: The Case For Mild Cystic Fibrosis Mutations, A Preventative Approach To CFTR-Related Diseases, And Expanding The Market To Decrease Prices By 99%
about 10 years ago
The Smackdown Becomes a CFF Milestone Donor
about 11 years ago
Estimated Prevalence of IVS8-5T in the U.S. Population
about 11 years ago
Announcing CF Smackdown grants
about 11 years ago
CF Smackdown launches new site
about 11 years ago
CF Smackdown leads the way at local CFF event
about 12 years ago
Smackdown Helps Forge CFF-Funded Splice Mutation Research Collaboration
about 12 years ago
Calling all 5Ts: Update on the Kalydeco/Residual CFTR study in Denver
about 12 years ago
NPR report on Kalydeco puts it in perspective
about 12 years ago
Kalydeco named "most important new drug of 2012"
about 12 years ago